Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Psyence Appoints Intellectual Property Expert to Its Board of Directors

Psyence Appoints Intellectual Property Expert to Its Board of Directors

  • Post published:July 11, 2023
  • Post category:Press Release
Read more about the article Bright Minds Announces Effective Date of Share Consolidation

Bright Minds Announces Effective Date of Share Consolidation

  • Post published:July 11, 2023
  • Post category:Press Release
Read more about the article Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023

Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023

  • Post published:July 11, 2023
  • Post category:Press Release
Read more about the article Psychedelic Research Bulletin: June 2023

Psychedelic Research Bulletin: June 2023

  • Post published:July 10, 2023
  • Post category:News/Psychedelics Research Review
Read more about the article American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

  • Post published:July 6, 2023
  • Post category:Press Release
Read more about the article Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

  • Post published:July 6, 2023
  • Post category:Press Release
Read more about the article FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES OF HEALTH RESEARCH PSILOCYBIN OPERATING GRANTS

FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES OF HEALTH RESEARCH PSILOCYBIN OPERATING GRANTS

  • Post published:July 6, 2023
  • Post category:Press Release
Read more about the article COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital

  • Post published:July 5, 2023
  • Post category:Press Release
Read more about the article Small Pharma Announces SPL028 R&D Strategy Update

Small Pharma Announces SPL028 R&D Strategy Update

  • Post published:July 5, 2023
  • Post category:Press Release
Read more about the article Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

  • Post published:July 5, 2023
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More